Quantcast

Cord Blood Registry Withdraws Opposition to Americord’s Trademark

March 17, 2014

NEW YORK, March 17, 2014 /PRNewswire/ — Americord announced today that it has successfully resolved a trademark case brought by rival cord blood bank Cord Blood Registry (or CBR Systems Inc). In the case, which was brought before the Trademark Trial And Appeal Board of the United States Patent and Trademark Office last year, CBR opposed Americord Registry’s use of the trademark CordAdvantage.

“We are pleased that CBR has withdrawn its opposition to Americord’s use of the trademark CordAdvantage,” said Martin Smithmyer, President and CEO of Americord. “We felt confident from the beginning that we had the right to use the CordAdvantage trademark, however, the process of defending a trademark can be a challenge, and we are glad to have it resolved.”

CordAdvantage refers to a specific product that Americord is developing under the direction of the company’s Executive Medical Director Dr. Robert Dracker. Currently in the late stages of development, CordAdvantage will utilize a proprietary process to maximize the volume of stem cells that can be harvested from cord blood found in the placenta immediately following the birth of a baby.

Americord filed the CordAdvantage trademark nearly two years ago. It has been an integral part of Americord’s brand identity since the company’s inception.

About Americord

Americord Registry is a leader in the advancement of
umbilical cord blood, cord tissue and placenta tissue banking.Americord collects, processes, and stores newborn stem cells from umbilical cord blood for future medical or therapeutic use, including the treatment of more than 80 blood diseases such as sickle cell anemia and leukemia. Founded in 2008, Americord is registered with the FDA and operates in all 50 states. The company’s laboratory is CLIA Certified, accredited by the AABB and complies with all federal and state guidelines and applicable licenses. Americord is headquartered in New York, NY. You may visit Americord’s cord blood blog or website at cordadvantage.com for more information. You may also find Americord on Facebook and follow the company on Twitter.

Contact: Andrew Flook
Americord Registry
866-503-6005
andrew.flook@cordadvantage.com

SOURCE Americord


Source: PR Newswire



comments powered by Disqus